Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion

ConclusionsAflibercept is an efficient alternative treatment for macular oedema secondary to CRVO refractory to ranibizumab. Good anatomic and functional result can be achieved with few injections. The maintenance of these results after 6 months is yet to be investigated.

Source: Acta Ophthalmologica - September 13, 2016 Category: Opthalmology Authors: V. Konidaris, K. Gorgoli, S. Burgula, J. Deane, S. Banerjee, T. Empeslidis Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research